Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Transcode Therapeutics Inc RNAZ

Healthcare Biotechnology
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique... see more

Recent & Breaking News (NDAQ:RNAZ)

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

GlobeNewswire 1 day ago

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

GlobeNewswire 3 days ago

TransCode Therapeutics Open Letter to Shareholders

GlobeNewswire November 12, 2024

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

GlobeNewswire November 5, 2024

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

GlobeNewswire October 23, 2024

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

GlobeNewswire October 10, 2024

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

GlobeNewswire September 17, 2024

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer

GlobeNewswire September 10, 2024

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

GlobeNewswire September 5, 2024

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

GlobeNewswire August 15, 2024

TransCode Therapeutics, Inc. Announces Closing of Public Offering

GlobeNewswire July 24, 2024

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

GlobeNewswire July 22, 2024

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire July 22, 2024

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

GlobeNewswire June 10, 2024

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

GlobeNewswire May 29, 2024

TransCode Therapeutics Open Letter to Shareholders

GlobeNewswire May 13, 2024

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

GlobeNewswire April 15, 2024

TransCode Therapeutics Reports 2023 Results; Provides Business Update

GlobeNewswire April 3, 2024

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

GlobeNewswire March 28, 2024

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

GlobeNewswire March 11, 2024